For patients with localized prostate cancer (PCa), tissue-based genomic classifiers (GCs) do not consistently influence risk classification or treatment decisions, according to a review. published in the Annals of Internal Medicine,
Amir Alishahi Tabriz, MD, Ph.D., MPH, from the Moffitt Cancer Center in Tampa, Florida, and colleagues conducted a systematic review to summarize the impact of the Decipher, Oncotype DX Genomic Prostate Score (GPS), and Prolaris GCs on Risk stratification and patient-clinician decisions regarding treatment choice among patients with localized PCa considering first-line treatment. Studies on risk classification and treatment choice after GC testing were independently identified by two investigators.
The researchers identified 10 studies that reported on risk reclassification after GC testing. Very low-risk or low-risk patients with PCa were more likely to have their risk levels classified as the same or lower in observational studies with a low risk for bias (GPS: 100 to 88.1%; Decipher: 87.2 to 82.9%; Prolaris :76.9%). GC testing with GPS reclassified 34.5 and 29.4% of very low-risk and low-risk patients, respectively, to a higher risk category in one randomized study.
Treatment decisions after GC testing either remained unchanged or slightly favored active surveillance based on 12 observational studies. However, in analyzes from a single randomized trial, fewer choices for active surveillance after GPS testing were seen.
“Although GC tests do not consistently influence risk classification or treatment decisions, the differences observed between observational and randomized studies highlight a need for well-designed trials to explore the role of GC tests in patients with newly diagnosed PCa considering first-line treatment,” the authors write.
More information:
Amir Alishahi Tabriz et al, Impact of Genomic Classifiers on Risk Stratification and Treatment Intensity in Patients With Localized Prostate Cancer, Annals of Internal Medicine (2025). DOI: 10.7326/ANNALS-24-00700
Syed Arsalan Ahmed Naqvi et al, The Promise and Challenges of Genomic Classifiers in Localized Prostate Cancer, Annals of Internal Medicine (2025). DOI: 10.7326/ANNALS-24-03630
2025 Health Day. All rights reserved.
Citation: Genomic classifier tests play heterogeneous role in prostate cancer risk classification (2025, January 21) retrieved 22 January 2025 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.